Investor · 1 deal
Every published round Emergent Medical Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| EBR Systems | Unnamed stage | 27 Aug 2019 | $30m | Participant | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Emergent Medical Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| EBR Systems | 27 Aug 2019 | 1 | 0 |
Fund closes reported for Emergent Medical Partners, as distinct from the investments it has made.
Companies Emergent Medical Partners has backed that another company then bought. An exit for the holding, not a deal Emergent Medical Partners did.
| Name | Role | Sources |
|---|---|---|
| Dr Thomas Fogarty | Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Emergent Medical Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A French cardiac specialist performed the first leadless left bundle branch area pacing implant using EBR Systems' wireless pacing device, with the announcement recalling the company's private equity backers.
EBR Systems' wireless cardiac pacing system won FDA Breakthrough Device Designation, bringing priority review, while its SOLVE CRT pivotal trial enrolls heart failure patients; the company counts Brandon Capital among its backers.
Cardiac pacing developer EBR Systems has completed a $30 million financing co-led by two Australian investors to finish its clinical trial, and has appointed John McCutcheon as president and chief executive.